Ryoncil

Mesoblast is a clinical-stage biotechnology company focused on the development of allogeneic cellular medicines for inflammatory diseases. The company utilizes its proprietary mesenchymal lineage adult stem cell technology to target conditions with high unmet medical needs, including cardiovascular diseases, spine orthopedic disorders, and immune-mediated diseases. Its lead product candidate, remestemcel-L (branded as Ryoncil), is designed to treat steroid-refractory acute graft-versus-host disease in children. Mesoblast has established a global footprint with operations in Australia, the United States, and Singapore, and maintains strategic partnerships for the commercialization of its cell therapy candidates.